Lifestyle and Dietary Pattern in Relation to Precursor Lesions of Colorectal Cancer and Cardiometabolic Diseases

January 7, 2024 updated by: Jingjing Jiao, Zhejiang University

Lifestyle and Dietary Pattern in Relation to Precursor Lesions of Colorectal Cancer and Cardiometabolic Diseases Among High-risk Populations in Lanxi, China

The association between lifestyle and dietary patterns with precursor lesions of colorectal cancer and cardiometabolic diseases is still unclear. This study is conducted in Jinhua, a city with a high prevalence of colorectal cancer in China, to assess the relationship between lifestyle and dietary factors with precursor lesions of colorectal cancer and cardiometabolic diseases.

Study Overview

Status

Active, not recruiting

Conditions

Detailed Description

Investigations of lifestyle and dietary factors in relation to precursor lesions of colorectal cancer and cardiometabolic diseases are limited in China. The investigators aim to collect the basic characteristics of participants at baseline, including sex, age, smoking, exercise, marriage, education level, dietary factors and so on, to assess the associations between lifestyle and dietary factors with precursor lesions of colorectal cancer and cardiometabolic diseases. This large cohort - the Lanxi Pre-colorectal Cancer Cohort (LP3C) also included several subcohorts consisting of patients with CVD, diabetes, hypertension, metabolic syndrome, obese/overweight or fatty liver disease. Results from this study will be valuable for colorectal cancer and cardiometabolic disease prevention in China.

Study Type

Observational

Enrollment (Estimated)

25000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • China
    • Zhejiang
      • Jinhua, Zhejiang, China, 321000
        • Lanxi Hospital of Traditional Chinese Medicine
      • Lanxi, Zhejiang, China, 321100
        • Lanxi Red Cross Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

45 years to 74 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Sampling Method

Probability Sample

Study Population

Subjects are eligible residents from 16 towns and villages of Jinhua, China.

Description

Inclusion Criteria:

  • Subject aged ≥45 and ≤74 years old
  • Subject has complete data on diet and follow-up time

Exclusion Criteria:

  • Colorectal cancer
  • Severe intestines problems

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Numbers of participants with polyps
Time Frame: From entry into the study (baseline:2018-2022) until 2028
All polyps
From entry into the study (baseline:2018-2022) until 2028

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Numbers of participants with different subtypes of polyps
Time Frame: From entry into the study (baseline:2018-2022) until 2028
Subtypes of polyps, including serrated polyps, hyperplastic polyps, sessile serrated polyps/adenoma
From entry into the study (baseline:2018-2022) until 2028
Numbers of participants with cardiometabolic diseases
Time Frame: From entry into the study (baseline:2018-2022) until 2028
Cardiometabolic diseases including cardiovascular disease, diabetes, and hypertension
From entry into the study (baseline:2018-2022) until 2028

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Numbers of participants died
Time Frame: From entry into the study (baseline:2018-2022) until 2028
All-cause and cause-specific mortality outcomes
From entry into the study (baseline:2018-2022) until 2028

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Zhejiang University

Collaborators

Lanxi Hospital of Traditional Chinese Medicine
Lanxi Red Cross Hospital

Investigators

  • Principal Investigator: Jingjing Jiao, Zhejiang University
  • Principal Investigator: Weifang Zheng, MD, Lanxi Red Cross Hospital
  • Principal Investigator: Pan Zhuang, Zhejiang University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 1, 2018

Primary Completion (Estimated)

December 1, 2024

Study Completion (Estimated)

May 1, 2028

Study Registration Dates

First Submitted

October 14, 2018

First Submitted That Met QC Criteria

October 14, 2018

First Posted (Actual)

October 17, 2018

Study Record Updates

Last Update Posted (Actual)

January 10, 2024

Last Update Submitted That Met QC Criteria

January 7, 2024

Last Verified

January 1, 2024

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • cohort- colorectal cancer

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cardiovascular Diseases

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bulgaria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe